Research and Markets: It Is Expected That Lithuania's Pharmaceutical Market Will Reach US$1,033 Million, Equal To US$316 Per Capita, by 2013

DUBLIN--(Business Wire)--
Research and
Markets(http://www.researchandmarkets.com/research/0164be/the_pharmaceutical)
has announced the addition of the "The Pharmaceutical Market: Lithuania" report
to their offering.

This in-depth pharmaceutical market report is ideal for executives wanting to
understand the key drivers in pharmaceutical markets and have access to a wealth
of statistical data. Each report opens with an outlook section that provides
analysis of the market, 5-year market forecasts, national data projections,
market outlook and key developments such as regulation, pricing/reimbursement,
intellectual property, health facilities and government policy. The report also
provides extensive background information, population trends, health status,
health expenditure, organisation & administration, hospital services, medical
personnel, healthcare development, market access information, trade data for raw
materials and finished products and essential industry contacts. Included with
the report are 3 free quarterly updated outlook reports, enabling you to keep up
to date with market developments for a year.

Executive Summary

The Republic of Lithuania is situated in north-eastern Europe and is largest of
the three Baltic States. It is bordered by Latvia, Belarus, Poland and by the
territory of the Russian Federation (Kalingrad Oblast). The population of
Lithuania is estimated at 3.4 million in 2008. Lithuania joined the EU in 2004.

Funding for healthcare in Lithuania is principally through the Compulsory Health
Insurance Fund. Compulsory insurance came into force in 1997, following a delay
in its implementation. It should provide free, basic treatment to the insured
population, but unofficial payments still occur, to cover the cost of
pharmaceuticals and staff wages. Private expenditure has increased in recent
years and is equal to 30.2% of total spending in 2008.

In 2008, the Lithuanian market for pharmaceuticals is estimated at US$747
million, or US$222 per capita. It is expected that the market will continue to
expand at a rate of 6.7% per annum, reaching US$1,033 million, equal to US$316
per capita, by 2013.

Around 80% of the pharmaceutical market is supplied by imports. In 2006,
Germany, Belgium and Latvia were the leading suppliers, accounting for almost
50% of imports. The value of imports has increased every year since 1999.

Sanitas, Lithuania's largest pharmaceutical company, recorded sales growth of
680% between 2004 and 2007 due to the acquisition of three pharmaceutical
companies in central Europe. Sanitas purchased Slovakia's Hoechst-Biotika in
July 2005, Poland's Jelfa in April 2006 and the Polish ointment producer
Homeofarm in December 2008. However, the company remains very small by
international standards.

Key Topics Covered:

* Executive Summary
* Introduction
* Current market size
* Generic usage
* 7. Market projections & outlook
* 8. Imports
* 9. Domestic manufacturing
* 11. Exports
* 13. Pharmaceutical regulations
* 14. Pricing & reimbursement
* 15. Intellectual property
* 16. Distribution & retail
* 17. Demographics
* 18. Healthcare system
* 19. Health expenditure
* 20. Healthcare infrastructure
* 21. Healthcare personnel
* 22. Directory
* 23. Methodology & sources
* 97. Appendix: healthcare statistics

Companies Mentioned:

Domestic Producers include:

* Sanitas

For more information visit
http://www.researchandmarkets.com/research/0164be/the_pharmaceutical

Source: Espicom Business Intelligence Ltd

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Copyright Business Wire 2009